The addition of an MR blocker to an ACE inhibitor or ARB significantly increases the risk of hyperkalemia (relative risk 3.74, 95% CI 2.30–6.09, p < 0.00001) [41]. The gene discussed is ACE; the disease is Hyperkalemia.